



# Clinical Trials of Texas, Inc.

Dedicated to the advancement of new medical therapies.

## Curriculum Vitae

### Albert Mosqueda, MD

7940 Floyd Curl, Ste. 1050  
San Antonio, Texas 78229

8401 Datapoint Drive, Ste. 401  
San Antonio, Texas 78229

#### EDUCATION

- 1984-1990 Bachelor of Arts in Biology and Doctor of Medicine, University of Missouri-Kansas, School of Medicine  
1990-1993 Resident Representative and Chief Resident, The Portland Program of Internal Medicine at Legacy Emanuel Hospital & Legacy Good Samaritan Hospital

#### LICENSURE AND CERTIFICATIONS

Texas Board Certified in Internal Medicine  
Texas Medical License, # L6535  
DEA License

#### MEMBERSHIPS

American College of Physician Executives  
American Medical Association  
Bexar County Medical Society  
Texas Medical Association

#### PROFESSIONAL EXPERIENCE

- 1993-1994 Chief Resident, The Portland Program of Internal Medicine at Legacy Emanuel Hospital & Legacy Good Samaritan Hospital  
1994-1998 Faculty Member, The Portland Program of Internal Medicine at Legacy Emanuel Hospital & Legacy Good Samaritan Hospital  
1994-1996 Medical Director, Emanuel Internal Medicine Associates  
1996-1998 Medical Director, Mullikin Medical Center - Emanuel  
2002 Area Medical Director, Mullikin Medical Centers- Oregon  
2003-Present Group Practice, San Antonio Preventative and Diagnostic Medicine, PA, San Antonio, Texas

#### RESEARCH AFFILIATION

- 2004-Present Clinical Trials of Texas, Inc., San Antonio, TX
- Principal Investigator
  - Sub-Investigator

#### COMMITTEES

- 1993-1994 Chairperson, Legacy Portland Hospitals Code Committee  
1993 - 1996 Chairperson, Resident Evaluation Committee, The Portland Program of Internal Medicine at Legacy Emanuel Hospital & Legacy Good Samaritan Hospital

*Albert Mosqueda, MD*  
2/5/2008

1994 - 1995 Chairperson, Legacy Portland Hospitals Anticoagulation Task Force  
 1993 - 1995 Legacy Portland Hospitals Department of Medicine Graduate Medical Education Committee  
 1997 - 2001 Chairperson, MMC - Oregon Compensation Committee  
 1998 MMC - Oregon Referral Expenditure Task Force  
 1998 - 1999 MMC - Oregon Hospitalist Task Force  
 1998 - 2002 MMC - Oregon Board of Directors  
 2001 - 2003 Member of Advisor Committee, Physician Resources Network  
 2002 - 2003 Member of Digital Imaging Initiative Working Group for Providence Health Systems

Administrative ("Business of Medicine") CME

- "Team Development: Creating the Consensus You Need to Succeed" – Ed O'Conner
- "Strategic Planning and Marketing" – Eric Berkowitz
- "Financial Management in a Time of Limited Resources" – Mark Covaleski
- "Managing Group Dynamics" – Sandra Gill
- "Quality Management: Setting the Standards" – David Nash
- "Collaborative Leadership in a Learning Organization" – Alain Gauthier
- "Leading from Within" – Steve Bucholtz
- "How Great Leaders Use Powerful Conversation to Win – Philip Harkin & Steve Williamson
- "The Shifting Sources of Power and Influence" – Charles Dwyer

Attended the 1998 Healthcare Forum Summit – Leadership For A Healthy 21<sup>st</sup> Century

**RESEARCH EXPERIENCE**

2007- Present; Double-Blind Follow-On Safety Study of XXXXX in Subjects Who Have Completed Participation in XXXXX Protocol XXXXX or XXXXX Protocol XXXXX

2007-Present; A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of XXXXX in Subjects Requiring NSAID Treatment

2007- Present; A Randomized-Withdrawal Phase III Study Evaluating the Safety and Efficacy of XXXXX Extended-Release (ER) in Subjects with Painful Diabetic Peripheral Neuropathy (DPN)

2007-Present; A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-Range-Finding, Parallel-Design, Phase 2 Trial of Oral XXXXX Administered to Patients with Irritable Bowel Syndrome with Constipation

2007-Present; A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular XXXXX in Subjects with Uncomplicated Acute Influenza

2006-Present; A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of XXXXX in Subjects with Type 2 Diabetes

2006-2007; A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of XXXXX and XXXXX to XXXXX and XXXXX in Subjects with Mixed Dyslipidemia

2006-2007; A Long-Term, Open-Label, Safety Extension Study of the Combination of XXXXX and XXXXX Therapy for Subjects with Mixed Dyslipidemia

2006-Present; A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of XXXXX (XXXXX) Compared with Placebo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No Response to a Selective Serotonin Reuptake Inhibitor or Serotonin-Norepinephrine Reuptake Inhibitor Alone or in Combination with a Benzodiazepine

2005-2007; A 12-Week, Multicenter, Double-Blind, Randomized Efficacy and Safety Study of XXXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome

2004-2005; A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXX for the Treatment of Painful Diabetic Neuropathy

1995-1996; Detection of Antibodies to HIV-1 in Specimens Obtained With The XXXXX Oral Specimen Collection Device, Protocol XXXXX

1994-1995; Detection of Antibodies to HIV-1 by Western Blot in Specimen Obtained With The XXXXX Oral Specimen Collection Device, Protocol XXXX

1994-1995; A Multicenter, Randomized, Partially-Blind, Parallel Group, Clinical Trail To Compare The Efficacy and Safety of Twice and Once Daily Subcutaneously Administered XXXXX and XXXXX in The Treatment of Patients With Deep Vein Thrombosis and Pulmonary Embolism

- Sub-investigator for the Portland, Oregon site of this international clinical study